MindWalk Holdings Corp. - Common Stock (HYFT)

MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives. MindWalk operates a proprietary BioNative AI platform built on patented HYFT® patterns—evolution shaped subsequence codes that link sequence, structure and function. These patterns underpin LensAI™, a software platform that harmonizes and analyzes diverse biological data to deliver actionable insights.

MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2026, on Monday, December 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period.

MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM.

MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025.

MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025.

MindWalk Holdings (NASDAQ: HYFT), a bio-native AI company, announced that its Board of Directors has authorized a share repurchase program allowing the company to buy back up to 2.3 million common shares, or approximately 5% of its 46.15 million shares outstanding, over a 12-month period beginning Oct. 15, 2025. CEO Jennifer Bath said the program reflects confidence in MindWalk’s long-term prospects and provides flexibility to repurchase shares when market prices diverge from intrinsic value, with purchases to be funded through existing cash, investments, or future cash flows.

MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value (the “Common Shares”) over the twelve-month period commencing on October 15th, 2025, and ending no later than October 15th, 2026 (the “Program”). This represents approximately 5% of the 46,154,188 Common Shares currently issued and outstanding.